ORBi: Detailled Reference

Article (Scientific journals)

Coll2-1 and Coll2-1NO2 as exemplars of collagen extracellular matrix turnover–biomarkers to facilitate the treatment of osteoarthritis?

Mobasheri, Ali; Lambert, Cécile; Henrotin, Yves

2019 • In Expert Review of Molecular Diagnostics, 19 (9), p. 803-812

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/247195

DOI
10.1080/14737159.2019.1646641

PubMed
31327279

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Coll2 1 and Coll2 1NO2 as exemplars of collagen extracellular matrix turnover biomarkers to facilitate the treatment of osteoarthritis copy.pdf

Publisher postprint (1.39 MB)

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Coll2-1; Coll2-1NO2; Osteoarthritis (OA)

Abstract :

[en] Introduction: Osteoarthritis (OA) is the most common form of arthritis. However, there are no structure or disease-modifying OA drugs (DMOADs). Introducing personalized healthcare to patients and health-care practitioners is a high priority for the management of arthritic and musculoskeletal diseases. However, there are no biomarker tools that can be used for patient stratification, disease management, and drug development. Biomarkers are capable of diagnosing and prognosing some arthritic and musculoskeletal diseases. Cartilage-based biomarkers have the potential to be used in this context to guide the precision treatment of OA. Areas covered: The aim of this review is to focus on the pre-clinical and clinical utility of the Coll2-1 and Coll2-1NO2 biomarkers as unique cartilage-based biomarkers that can guide the development of new treatments for OA. This expert report will begin with a background to collagens and their important biomechanical roles in the musculoskeletal system, but particularly cartilage, before exploring the data and scientific evidence to support the utility of Coll2-1 and Coll2-1NO2 as unique biomarkers. Expert opinion: This review summarises the authors’ expert view on the pre-clinical and clinical utility of the Coll2-1 and Coll2-1NO2 biomarkers and their potential for use as drug development tools. © 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.

Disciplines :

Rheumatology

Author, co-author :

Mobasheri, Ali; Department of Regenerative Medicine, State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania, Centre for Sport, Exercise and Osteoarthritis Versus Arthritis, Queen’s Medical Centre, Nottingham, United Kingdom, European Commission, The D-BOARD FP7 Consortium, United Kingdom, The APPROACH IMI Consortium, United Kingdom, Research Unit of Medical Imaging, Physics and Technology, Faculty of Medicine, University of Oulu, Oulu, Finland

Lambert, Cécile ; Université de Liège - ULiège > Département des sciences de la motricité > Unité de recherche sur l'os et le cartilage (U.R.O.C.)

Henrotin, Yves ; Université de Liège - ULiège > Département des sciences de la motricité > Unité de recherche sur l'os et le cartilage (U.R.O.C.)

Language :

English

Title :

Coll2-1 and Coll2-1NO2 as exemplars of collagen extracellular matrix turnover–biomarkers to facilitate the treatment of osteoarthritis?

Publication date :

2019

Journal title :

Expert Review of Molecular Diagnostics

ISSN :

1473-7159

eISSN :

1744-8352

Publisher :

Taylor and Francis Ltd

Volume :

19

Issue :

9

Pages :

803-812

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 06 May 2020

Statistics

Number of views

86 (3 by ULiège)

Number of downloads

3 (3 by ULiège)

More statistics

Scopus citations^®

20

Scopus citations^®
without self-citations

16

OpenCitations

15

OpenAlex citations

24

Bibliography

Palazzo C, Ravaud J-F, Papelard A, et al. The burden of musculoskeletal conditions. PLoS One. 2014;9(3):e90633. doi:10.1371/journal.pone.0090633.ecollection 2014.
Helmick CG, Felson DT, Lawrence RC, et alet alEstimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58(1):15–25.
National Clinical Guideline Centre (UK). Osteoarthritis: care and management in adults. London: National Institute for Health and Care Excellence (UK). 2014
Kingsbury SR, Gross HJ, Isherwood G, et al. Osteoarthritis in Europe: impact on health status, work productivity and use of pharmacotherapies in five European countries. Rheumatology. 2014;53(5):937–947.
Ulrich-Vinther M, Maloney MD, Schwarz EM, et al. Articular cartilage biology. J Am Acad Orthop Surg. 2003;11(6):421–430.
Archer CW, Francis-West P., The chondrocyte. Int J Biochem Cell Biol. 2003;35(4):401–404.
Buckwalter JA, Mankin HJ., Articular cartilage: degeneration and osteoarthritis, repair, regeneration, and transplantation. Instr Course Lect. 1998;47:487–504.
Szychlinska MA, Trovato FM, Di Rosa M, et al. Co-Expression and co-localization of Cartilage Glycoproteins CHI3L1 and Lubricin in osteoarthritic cartilage: morphological, immunohistochemical and gene expression profiles. Int J Mol Sci. 2016;17(3):359.
Di Rosa M, Szychlinska MA, Tibullo D, et al. Expression of CHI3L1 and CHIT1 in osteoarthritic rat cartilage model. A morphological study. Eur J Histochem. 2014;58(3):2423.
Musumeci G, Tovato FM, Loreto C, et al. Lubricin expression in human osteoarthritic knee meniscus and synovial fluid: a morphological, immunohistochemical and biochemical study. Acta Histochem. 2014;116(5):965–972.
Henrotin Y, Addison S, Kraus V, et al. Type II collagen markers in osteoarthritis: what do they indicate?. Curr Opin Rheumatol. 2007;19(5):444–450.
Roos EM, Arden NK. Strategies for the prevention of knee osteoarthritis. Nat Rev Rheumatol. 2015; 12(2):92-101.
Ricard-Blum S. The collagen family. Cold Spring Harb Perspect Biol. 2011;3(1):a004978.
Boot-Handford RP, Tuckwell DS. Fibrillar collagen: the key to vertebrate evolution? A tale of molecular incest. Bioessays. 2003;25(2):142–151.
Sanchez C, Bay-Jensen AC, Pap T, et al. Chondrocyte secretome: a source of novel insights and exploratory biomarkers of osteoarthritis. Osteoarthritis Cart. 2017;25(8):1199–1209.
Gelse K, Pöschl E, Aigner T. Collagens–structure, function, and biosynthesis. Adv Drug Deliv Rev. 2003;55(12):1531–1546.
Cohen MM. The new bone biology: pathologic, molecular, and clinical correlates. Am J Med Genet A. 2006;140(23):2646–2706.
Dalgleish R. The human type I collagen mutation database. Nucleic Acids Res. 1997;25(1):181–187.
Heinegård D, Saxne T. The role of the cartilage matrix in osteoarthritis. Nat Rev Rheumatol. 2011;7(1):50–56.
Garvican ER, Vaughan-Thomas A, Innes JF, et al. Biomarkers of cartilage turnover. Part 1: markers of collagen degradation and synthesis. Vet J. 2010;185(1):36–42.
Price JS, Till SH, Bickerstaff DR, et al. Degradation of cartilage type II collagen precedes the onset of osteoarthritis following anterior cruciate ligament rupture. Arthritis Rheum. 1999;42(11):2390–2398.
Fraser A, Fearon U, Billinghurst RC, et alet alTurnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation. Arthritis Rheum. 2003;48(11):3085–3095.
Adam M, Deyl Z. Degenerated annulus fibrosus of the intervertebral disc contains collagen type II. Ann Rheum Dis. 1984;43(2):258–263.
Luo Y, Sinkeviciute D, He Y, et alet alThe minor collagens in articular cartilage. Protein Cell. 2017;8(8):560–572.
Ameye LG, Deberg M, Oliveira M, et al. The chemical biomarkers C2C, Coll2-1, and Coll2-1NO2 provide complementary information on type II collagen catabolism in healthy and osteoarthritic mice. Arthritis Rheum. 2007;56(10):3336–3346.
Verwilghen D, Busoni V, Gangl M, et alet alRelationship between biochemical markers and radiographic scores in the evaluation of the osteoarticular status of Warmblood stallions. Res Vet Sci. 2009;87(2):319–328.
Verwilghen DR, Martens A, Busschers E, et alet alColl2-1, Coll2-1NO2 and myeloperoxidase concentrations in the synovial fluid of equine tarsocrural joints affected with osteochondrosis. Vet Res Commun. 2011;35(7):401–408.
Verwilghen DR, Enzerink E, Martens A, et alet alRelationship between arthroscopic joint evaluation and the levels of Coll2-1, Coll2-1NO(2), and myeloperoxidase in the blood and synovial fluid of horses affected with osteochondrosis of the tarsocrural joint. Osteoarthr Cartil. 2011;19(11):1323–1329.
Huebner JL, Williams JM, Deberg M, et al. Collagen fibril disruption occurs early in primary guinea pig knee osteoarthritis. Osteoarthr Cartil. 2010;18(3):397–405.
Horcajada MN, Sanchez C, Membrez Scalfo F, et alet alOleuropein or rutin consumption decreases the spontaneous development of osteoarthritis in the Hartley guinea pig. Osteoarthr Cartil. 2015;23(1):94–102.
Henrotin Y, Patrier S, Pralus A, et al. Protective actions of oral administration of bifidobacterium longum CBi0703 in spontaneous osteoarthritis in dunkin hartley guinea pig model. Cartilage. 2019.
Deberg MA, Labasse AH, Collette J, et al. One-year increase of Coll 2-1, a new marker of type II collagen degradation, in urine is highly predictive of radiological OA progression. Osteoarthritis Cart. 2005;13(12):1059–1065.
Deberg M, Labasse A, Christgau S, et alet alNew serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis Cart. 2005;13(3):258–265.
Deberg M, Dubuc JE, Labasse A, et alet alOne-year follow-up of Coll2-1, Coll2-1NO2 and myeloperoxydase serum levels in osteoarthritis patients after hip or knee replacement. Ann Rheum Dis. 2008;67(2):168–174.
Joseph GB, Nevitt MC, McCulloch CE, et al. Associations between molecular biomarkers and MR-based cartilage composition and knee joint morphology: data from the Osteoarthritis Initiative. Osteoarthritis Cart. 2018;26(8):1070–1077.
Bliddal H, Christensen R. The treatment and prevention of knee osteoarthritis: a tool for clinical decision-making. Expert Opin Pharmacother. 2009;10(11):1793–1804.
Runhaar J, de Vos BC, van Middelkoop M, et al. Prevention of incident knee osteoarthritis by moderate weight loss in overweight and obese females. Arthritis Care Res (Hoboken). 2016;68(10):1428–1433.
Bartels EM, Henrotin Y, Bliddal H, et al. Relationship between weight loss in obese knee osteoarthritis patients and serum biomarkers of cartilage breakdown: secondary analyses of a randomised trial. Osteoarthr Cartil. 2017;25(10):1641–1646.
Bellamy N, Campbell J, Robinson V, et al. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006;19 (2):CD005321.
Henrotin Y, Chevalier X, Deberg M, et alet alEarly decrease of serum biomarkers of type II collagen degradation (Coll2-1) and joint inflammation (Coll2-1 NO₂) by hyaluronic acid intra-articular injections in patients with knee osteoarthritis: a research study part of the Biovisco study. J Orthop Res. 2013;31(6):901–907.
Henrotin Y, Berenbaum F, Chevalier X, et al. Reduction of the serum levels of a specific biomarker of cartilage degradation (Coll2-1) by hyaluronic acid (KARTILAGE® CROSS) Compared to placebo in painful knee osteoarthritis patients: the EPIKART Study, a pilot prospective comparative randomized double blind trial. BMC Musculoskelet Disord. 2017;18(1):222.
Henrotin Y, Hauzeur J-P, Bruel P, et al. Intra-articular use of a medical device composed of hyaluronic acid and chondroitin sulfate (Structovial CS): effects on clinical, ultrasonographic and biological parameters. BMC Res Notes. 2012;5:407.
de Vos RJ, van Veldhoven PLJ, Moen MH, et al. Autologous growth factor injections in chronic tendinopathy: a systematic review. Br Med Bull. 2010;95:63–77.
Fioravanti C, Frustaci I, Armellin E, et al. Autologous blood preparations rich in platelets, fibrin and growth factors. Oral Implantol (Rome). 2015;8(4):96–113.
Fawzy RM, Hashaad NI, Mansour AI. Decrease of serum biomarker of type II Collagen degradation (Coll2-1) by intra-articular injection of an autologous plasma-rich-platelet in patients with unilateral primary knee osteoarthritis. Eur J Rheumatol. 2017;4(2):93–97.
Guan VX, Mobasheri A, Probst YC. A systematic review of osteoarthritis prevention and management with dietary phytochemicals from foods. Maturitas. 2019;122:35–43.
Henrotin Y, Priem F, Mobasheri A. Curcumin: a new paradigm and therapeutic opportunity for the treatment of osteoarthritis: curcumin for osteoarthritis management. Springerplus. 2013;2(1):56.
Henrotin Y, Gharbi M, Dierckxsens Y, et alet alDecrease of a specific biomarker of collagen degradation in osteoarthritis, Coll2-1, by treatment with highly bioavailable curcumin during an exploratory clinical trial. BMC Complement Altern Med. 2014;14:159.
Möller I, Gharbi M, Martinez Serrano H, et al. Effect of chondroitin sulfate on soluble biomarkers of osteoarthritis: a method to analyze and interpret the results from an open-label trial in unilateral knee osteoarthritis patients. BMC Musculoskelet Disord. 2016;17(1):416.
Rego-Pérez I, Fernández-Moreno M, Deberg M, et alet alMitochondrial DNA haplogroups modulate the serum levels of biomarkers in patients with osteoarthritis. Ann Rheum Dis. 2010;69(5):910–917.
Richette P, Eymard C, Deberg M, et alet alIncrease in type II collagen turnover after iron depletion in patients with hereditary haemochromatosis. Rheumatology. 2010;49(4):760–766.
Oliveria SA, Felson DT, Cirillo PA, et al. Body weight, body mass index, and incident symptomatic osteoarthritis of the hand, hip, and knee. Epidemiology. 1999;10(2):161–166.
Haugen IK, Ramachandran VS, Misra D, et alet alHand osteoarthritis in relation to mortality and incidence of cardiovascular disease: data from the Framingham heart study. Ann Rheum Dis. 2015;74(1):74–81.
Punzi L, Ramonda R, Deberg M, et alet alColl2-1, Coll2-1NO2 and myeloperoxidase serum levels in erosive and non-erosive osteoarthritis of the hands. Osteoarthr Cartil. 2012;20(6):557–561.
Henrotin Y, Labasse A, Franck T, et al. Collagen catabolism through Coll2-1 and Coll2-1NO2 and myeloperoxidase activity in marathon runners. Springerplus. 2013;2(1):92.
Henrotin Y, Fonck M, Costes B, et al. Serum levels of Coll2-1, a specific biomarker of cartilage degradation, are not affected by sampling conditions, circadian rhythm, seasonality and physical activity. Osteoarthritis Cartilage. 2019;27(1):S101.
Cohen-Solal M, Funck-Brentano T, Hay E. Animal models of osteoarthritis for the understanding of the bone contribution. Bonekey Rep. 2013;2:422.
Lotz M, Martel-Pelletier J, Christiansen C, et alet alValue of biomarkers in osteoarthritis: current status and perspectives. Ann Rheum Dis. 2013;72(11):1756–1763.
Bauer DC, Hunter DJ, Abramson SB, et al. Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthr Cartil. 2006;14(8):723–727.
van Spil WE, DeGroot J, Lems WF, et al. Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review applying the consensus BIPED criteria. Osteoarthr Cartil. 2010;18(5):605–612.
Kraus VB, Burnett B, Coindreau J, et al. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthr Cartil. 2011;19(5):515–542.
Lambert C, Borderie D, Rannou F, et al. The Coll2-1 peptide of collagen type II: a new actor of synovitis in osteoarthritis. Osteoarthritis Cartilage. 2018;26(Suppl 1):s120–s121.
Andersson MLE, Thorstensson CA, Roos EM, et al. Serum levels of cartilage oligomeric matrix protein (COMP) increase temporarily after physical exercise in patients with knee osteoarthritis. BMC Musculoskelet Disord. 2006;7(7):98.
Cattano NM, Driban JB, Barbe MF, et al. Physical activity levels and quality of life relate to collagen turnover and inflammation changes after running. J Orthop Res. 2017;35(3):612–617.
Denning WM, Winward JG, Pardo MB, et al. Body weight independently affects articular cartilage catabolism. J Sports Sci Med. 2015;14(2):290–296.
Mündermann A, King KB, Smith RL, Andriacchi TP. Change in serum COMP concentration due to ambulatory load is not related to knee OA status. J Orthop Res. 2009;27(11):1408–1413.
Neidhart M, Müller-Ladner U, Frey W, et alet alIncreased serum levels of non-collagenous matrix proteins (cartilage oligomeric matrix protein and melanoma inhibitory activity) in marathon runners. Osteoarthritis Cart. 2000;8(3):222–229.
Kong SY, Stabler TV, Criscione LG, et al. Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis. Arthritis Rheum. 2006;54(8):2496–2504.
Karsdal MA, Byrjalsen I, Bay-Jensen AC, et al. Biochemical markers identify influences on bone and cartilage degradation in osteoarthritis–the effect of sex, Kellgren-Lawrence (KL) score, body mass index (BMI), oral salmon calcitonin (sCT) treatment and diurnal variation. BMC Musculoskelet Disord. 2010;11:125.
Quintana DJ, Garnero P, Huebner JL, et al. PIIANP and HELIXII diurnal variation. Osteoarthr Cartil. 2008;16(10):1192–1195.
Bartels EM, Christensen R, Christensen P, et alet alEffect of a 16 weeks weight loss program on osteoarthritis biomarkers in obese patients with knee osteoarthritis: a prospective cohort study. Osteoarthr Cartil. 2014;22(11):1817–1825.
Jordan JM, Luta G, Stabler T, et alet alEthnic and sex differences in serum levels of cartilage oligomeric matrix protein: the Johnston county osteoarthritis project. Arthritis Rheum. 2003;48(3):675–681.
Kraus VB, Collins JE, Hargrove D, et alet alPredictive validity of biochemical biomarkers in knee osteoarthritis: data from the FNIH OA Biomarkers Consortium. Ann Rheum Dis. 2017;76(1):186–195.
Mouritzen U, Christgau S, Lehmann HJ, et al. Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index. Ann Rheum Dis. 2003;62(4):332–336.
Rousseau JC, Zhu Y, Miossec P, et al. Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis. Osteoarthr Cartil. 2004;12(6):440–447.
Verma P, Dalal K. Serum cartilage oligomeric matrix protein (COMP) in knee osteoarthritis: a novel diagnostic and prognostic biomarker. J Orthop Res. 2013;31(7):999–1006.
BEST (Biomarkers, EndpointS, and other Tools) Resource FDA-NIH biomarker working group. silver spring (MD): food and drug administration (US). Bethesda (MD): National Institutes of Health (US); 2016.

Similar publications